Calcium channel blockers (CCBs) and angiotensin II receptor blockers (ARBs) may be associated with a reduced risk of dementia, according to a systematic review and network meta-analysis conducted by researchers from the Netherlands.
Use of the antipsychotic drug pimavanserin led to a substantial reduction in psychosis symptoms in individuals with dementia regardless of severity or subtype, according to the results of the HARMONY trial presented at AAIC 2020.
A new blood test for plasma P-tau217* accurately differentiates Alzheimer's disease (AD) from other neurodegenerative diseases — showing promise as a blood-based biomarker for early detection of AD, according to a study presented at the AAIC 2020 Meeting.
Risk factors for Alzheimer’s disease (AD) may be present as early as adolescence and young adulthood, data presented at AAIC 2020 have shown, highlighting the importance of addressing these factors early in the fight against AD and other dementias.
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.
Invasive fungal infections, particularly those caused by Candida species, are common in hospitalized, immunocompromised, or critically ill patients and are associated with considerable morbidity and mortality.